U.S. Appln. No. 09/476,485 Amendment and Response dated February 19, 2004 Reply to Office Action dated November 19, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the Application:

Listing of Claims:

Claim 1-72 (canceled)

Claim 73 (new): A pharmaceutical formulation comprising:

- (a) a pharmaceutically acceptable carrier; and
- (b) a FRIL family member molecule that:
 - (1) binds to a normally glycosylated FLT3 receptor;
 - (2) preserves progenitor cells; and
- (3) is encoded by a first nucleic acid molecule that hybridizes under stringent conditions to a second nucleic acid having a nucleotide sequence complementary to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 5, and SEQ ID NO: 7.

Claim 74 (new): A pharmaceutical formulation comprising:

- (a) a pharmaceutically acceptable carrier; and
- (b) a FRIL family member molecule that:
 - (1) binds to a normally glycosylated FLT3 receptor;
 - (2) preserves progenitor cells; and
- (3) has at least 95% amino acid sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO: 8.

Claim 75 (new): The pharmaceutical formulation of claim 73 or 74, wherein administration of an effective amount of said formulation to a subject undergoing a therapeutic treatment having progenitor-cell depleting activity alleviates or reduces said progenitor-cell depleting activity.

U.S. Appln. No. 09/476,485
Amendment and Response dated February 19, 2004
Reply to Office Action dated November 19, 2003

Claim 76 (new): The pharmaceutical formulation of claim 75, wherein said subject is a human undergoing treatment for cancer.

Claim 77 (hew): The pharmaceutical formulation of claim 75, wherein said therapeutic treatment is selected from the group consisting of radiotherapy, chemotherapy, or a combination of radiotherapy and chemotherapy.

Claim 78 (hew): The pharmaceutical formulation of claim 77, wherein said chemotherapy comprises administration of a chemotherapeutic selected from the group consisting of cytarabine, doxorubicin, and 5-fluorouracil.

Claim 79 (new): The pharmaceutical formulation of claim 73 or 74, wherein said pharmaceutical carrier is suitable for parenteral administration.

Claim 80 (new): The pharmaceutical formulation of claim 79 wherein said parenteral administration is selected from the group consisting of intravenous, intra-arterial, subcutaneous, intramuscular, intraperitoneal and intra-marrow administration.

Claim 81 (new): The pharmaceutical formulation of claim 73 or 74 wherein said FRIL family member molecule comprises the amino acid sequence of SEQ ID NO: 2.

Claim 82 (new): The pharmaceutical formulation of claim 73 or 74 wherein said FRIL family member molecule comprises the amino acid sequence of SEQ ID NO:6.

Claim 83 (hew): The pharmaceutical formulation of claim 73 or 74 wherein said FRIL family member molecule comprises the amino acid sequence of SEQ ID NO: 8.